Subtype
Prostate Neoplasm
CI-CAN-00003778Explore in graph →
Non-malignant1,453 active trials24 approved drugs58 evidence items
Loading cancer entity…
Subtype
CI-CAN-00003778Explore in graph →
Clinical trials
6,547 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06707961 | Prognostic Study of Via Dynamic Change of PCA3 mRNA in Drainage Fluid After Radical Prostatectomy | not yet recruiting | — | 100 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | Nov 27, 2024 | clinicaltrials |
| NCT06707974 | Prognostic Study of Via Dynamic Change of dT-DNA in Drainage Fluid After Radical Prostatectomy | not yet recruiting | — | 100 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
| 1 |
| Nov 27, 2024 |
| clinicaltrials |
| NCT05393791 | Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC(ANZadapt) | recruiting | Phase 2 | 168 | Leiden University Medical CenterOTHER | 2 | Nov 26, 2024 | clinicaltrials |
| NCT03891732 | MRI Prostate for Chinese Men Being Screened for Prostate Cancer | active not recruiting | — | 690 | Chinese University of Hong KongOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT03845166 | A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors(STELLAR-001) | active not recruiting | Phase 1 | 325 | ExelixisINDUSTRY | 10 | Nov 19, 2024 | clinicaltrials |
| NCT04879563 | Artificial Intelligence Supporting CAncer Patients Across Europe - the ASCAPE Project(ASCAPE) | active not recruiting | Phase 2 | 500 | Region Örebro CountyOTHER | 4 | Nov 19, 2024 | clinicaltrials |
| NCT05933876 | The Impact of Radiotherapy on Oligometastatic Cancer | recruiting | — | 2,000 | Institut Investigacio Sanitaria Pere VirgiliOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT05656573 | CART-PSMA Cells for Advanced Prostate Cancer | recruiting | Phase 1 | 20 | Nova Therapeutics LLCINDUSTRY | 1 | Nov 15, 2024 | clinicaltrials |
| NCT06027892 | Two-fraction Versus Five-fraction Stereotactic Radiotherapy for Localized Prostate Cancer(SABR-Dual) | recruiting | N/A | 562 | Rabin Medical CenterOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT01957436 | A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer(PEACE1) | active not recruiting | Phase 3 | 1,173 | UNICANCEROTHER | 7 | Nov 12, 2024 | clinicaltrials |
| NCT06665932 | Stereotactic Radiotherapy of Prostate Cancer With Reduction of Safety Margins | recruiting | N/A | 100 | University Hospital OstravaOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06683066 | Study on Human Bioequivalence of Triprerelin Acetate for Injection | recruiting | Phase 1 | 120 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06685562 | The 4D PICTURE Project: Evaluating Metro Mapping As a Method to Support Shared Decision Making in Oncology | recruiting | — | 500 | Leiden University Medical CenterOTHER | 3 | Nov 12, 2024 | clinicaltrials |
| NCT04430192 | Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy(LuTectomy) | active not recruiting | Phase 1 / Phase 2 | 20 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT02899312 | PSMA PET/CT for Assessment of Recurrent Prostate Cancer | active not recruiting | — | 2,244 | British Columbia Cancer AgencyOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT05001477 | Customized TULSA-PRO Ablation Registry(CARE) | recruiting | — | 1,000 | Profound Medical Inc.OTHER | 1 | Nov 6, 2024 | clinicaltrials |
| NCT06579417 | ART-Pro: Clinical Trial Evaluating Biparametric MRI and Advanced, Quantitative Diffusion MRI for Detection of Prostate Cancer(ART-Pro) | recruiting | — | 500 | University of California, San DiegoOTHER | 2 | Nov 6, 2024 | clinicaltrials |
| NCT06662708 | Artificial Intelligence Models for Precision Prediction and Treatment of Prostate Cancer | not yet recruiting | N/A | 200 | Shao PengfeiOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT06663007 | RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure | recruiting | Phase 1 / Phase 2 | 72 | Tianjin Medical University Second HospitalOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT06584279 | Diagnostic Value of MRI-targeted Plus Index-lesion-ipsilaterally Systematic Biopsy for Biopsy-naive Men At Risk of Prostate Cancer | recruiting | — | 563 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Oct 24, 2024 | clinicaltrials |
| NCT06617481 | PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence | recruiting | Phase 2 | 30 | AdventHealthOTHER | 1 | Oct 24, 2024 | clinicaltrials |
| NCT06655259 | Combination of TURP and Standard Systemic Therapy for MPCa(CTUSMEP01) | recruiting | Phase 2 | 200 | Fudan UniversityOTHER | 1 | Oct 23, 2024 | clinicaltrials |
| NCT05558007 | Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients | recruiting | Phase 2 | 72 | Biozeus Biopharmaceutical S.A.INDUSTRY | 1 | Oct 22, 2024 | clinicaltrials |
| NCT06636682 | FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer | recruiting | Phase 2 | 100 | Cellvax Therapeutics IncINDUSTRY | 1 | Oct 21, 2024 | clinicaltrials |
| NCT05629494 | Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test(ADAPT-PSA) | recruiting | Phase 4 | 198 | Albany Medical CollegeOTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT06274892 | Remote Monitoring of Patient Reported Outcomes to Improve the Efficacy of the Acute Phase Radiotherapy Review Process(PROMOTE) | recruiting | N/A | 124 | University Health Network, TorontoOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT06636747 | High Resolution Diffusion Weighted Imaging in Prostate | recruiting | — | 500 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06637267 | Prospective Evaluation of Proclarix® Test to Improve Risk Stratification in Men Scheduled for MpMRI and Prostate Biopsy in Cantonal Hospital Aarau | recruiting | — | 480 | Kantonsspital AarauOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05215574 | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 130 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Oct 10, 2024 | clinicaltrials |
| NCT05129605 | Prostate Cancer Genetic Risk Evaluation and Screening Study(PROGRESS) | recruiting | — | 400 | Massachusetts General HospitalOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT06634173 | The Diagnostic Value of FAPI PET/CT in Staging of Newly Diagnosed Prostate Cancer(proFAPI) | not yet recruiting | N/A | 30 | The Netherlands Cancer InstituteOTHER | 0 | Oct 9, 2024 | clinicaltrials |
| NCT06630962 | Evaluating the Impact of Financial Navigation on Financial Catastrophe and Distress for Cancer Care(COST-FIN) | recruiting | N/A | 200 | Northwestern UniversityOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT06626386 | Determination of Prostate-specific Antigen in Capillary Blood (PSA-Cap)(PSA-Cap) | recruiting | — | 200 | Heinrich-Heine University, DuesseldorfOTHER | 1 | Oct 3, 2024 | clinicaltrials |
| NCT03230734 | Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer(RAPSON) | active not recruiting | Phase 2 | 70 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06071195 | All-in-One Prostate Cancer Staging with MRI(AllinOne_MRI) | recruiting | — | 400 | European Institute of OncologyOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06614751 | A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway | not yet recruiting | Phase 1 | 112 | Danatlas Pharmaceuticals Co., LtdINDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06612580 | 68Ga-AAZTA-NI-093 PET/CT: First-in-human Study | recruiting | Early Phase 1 | 10 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT04571840 | Prostate Imaging Using MRI +/- Contrast Enhancement(PRIME) | active not recruiting | N/A | 500 | University College, LondonOTHER | 15 | Sep 23, 2024 | clinicaltrials |
| NCT05100121 | To Live Better After Prostate Cancer Treatment:(CAPPRIS) | recruiting | N/A | 40 | Karolinska InstitutetOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05613023 | A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT(PACE-NODES) | recruiting | Phase 3 | 1,128 | Institute of Cancer Research, United KingdomOTHER | 3 | Sep 19, 2024 | clinicaltrials |
| NCT06184464 | Prostatic Size Reduction Following of Leuprorelin Acetate(PROSTSIZE) | recruiting | — | 40 | Consorci Sanitari de TerrassaOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06521710 | Nerve Grafting Technique to Preserve Erectile Function in Patients Undergoing Robotic Assisted Radical Prostatectomy(NR-RALP) | recruiting | N/A | 10 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06585007 | Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer(MEDCARE) | recruiting | Phase 3 | 246 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Sep 5, 2024 | clinicaltrials |
| NCT05714774 | Evaluation of Different Methods of Ultrasound Image Analysis for Real-time Monitoring of HIFU Prostate Cancer Treatment(ELASTO-US) | recruiting | N/A | 40 | Hospices Civils de LyonOTHER | 1 | Sep 4, 2024 | clinicaltrials |
| NCT05361902 | A First Step Towards Ultra-hypofractionation for Unfavourable Intermediate and High-risk Prostate Cancer(UPRATE) | active not recruiting | N/A | 35 | Erasmus Medical CenterOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT06575257 | Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate Cancer | recruiting | Phase 2 | 80 | Xijing HospitalOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT06279260 | National Robotics-Assisted Radical Prostatectomy Database(RASOR) | recruiting | — | 10,000 | Melbourne HealthOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT06325774 | Radical Hypofractionated Radiotherapy for Localized Prostate Cancer | recruiting | N/A | 20 | Changhai HospitalOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT06325995 | Hypofractionated Post-prostatectomy Radiotherapy (HYPORT)for Localized Prostate Cancer | recruiting | N/A | 428 | Changhai HospitalOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT06524219 | Comparison of Nerve-sparing Techniques in Radical Prostatectomy for Oncological Outcome and Functional Recovery. | not yet recruiting | — | 150 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Aug 19, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Nov 27, 2024source: clinicaltrials